Alexion Pharmaceuticals Inc. not only gained the FDA's approval on Oct. 23 for Strensiq (asfotase alfa) as a treatment for patients with perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP), but the win also garnered the company a rare pediatric disease priority review voucher (PRV), potentially putting hundreds of millions of dollars in the firm's pocket.
Shares of Alexion rose $5.24 on Oct. 23, or 3.1%, before closing at $171.16, up $4.40, or 2.6%.